This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
A decision analytic tree model was used to determine the cost-effectiveness of the EHEP. Two prediction models were used to estimate the economic and life impact of the EHEP. The first model used hypertension prevalence rates as the basis of estimation, while the other used the incidence rate as the basis of prediction.
Sources searched to identify primary studies
Hypertension prevalence, incidence rates and the EHEP participation rates were derived from the 25,174 and 24,157 elderly residents of Kaohsiung city who participated in the 1996 and 1997 EHEP. Medication compliance rates and rates of hypertension screening (other than the EHEP) were derived from anecdotal evidence from Taiwan population studies; when unavailable, these were derived from international studies. The authors made assumptions about the probability of suffering a stroke.
Methods used to judge relevance and validity, and for extracting data
Nurses at four Kaohsiung city hospitals measured blood pressure as part of the EHEP. The 1996 database was used for the prevalence rate, while the incidence rate was based on elders who attended both the 1996 and 1997 EHEP. The authors provided no details of the review of the literature they undertook to derive other variables used in the model. However, they did report that generally a medium value was adopted to avoid bias in their evaluation. The authors made three assumptions about the probability of suffering a stroke:
EHEP elders still faced a probability of suffering a stroke whether or not they sought active treatment;
the percentage identified as hypertensive for the non-EHEP group was the same as that for the EHEP group; and those who were not screened for hypertension might not have known their blood pressure, and consequently they would not have benefited from medical attention.
Measure of benefits used in the economic analysis
The measure of benefits used was the loss of active life-days due to stroke. This used information on the loss in qualityadjusted life-years (QALYs) after stroke, based on a published study (Weinstein and Stanston 1977, see 'Other Publications of Related Interest' for bibliographic details).
Direct costs
The direct costs included in the analysis appear to have been those to the health care service. Specifically, the costs of hypertension screening, hypertension outpatient treatment and the direct costs associated with stroke (including hospitalisation, home care and nursing home expenses). The direct medical costs, both of stroke and hypertension, were derived from claims data from the Bureau of National Health Insurance. The cost of hypertension screening was based on the EHEP cost, which was the payment for the workload of each blood pressure reading. The authors did not report the time period during which the costs could be incurred. However, in their list of model parameters they included a discount rate of 5% as one of them, although they did not report whether this rate applied to the outcomes, costs or both. The price year was not reported. The study reported the average total costs. The authors reported the unit cost of each resource used.
The Elderly Health Examination Programme (EHEP) was a cost-effective programme with health and social welfare policy implications.
CRD COMMENTARY -Selection of comparators
A justification was given for using a non-EHEP programme as the comparator, namely that 73.5% of elderly Kaohsiung residents did not participate in the study. You should consider whether the comparator used represents current practice in your own setting.
Validity of estimate of measure of effectiveness
The parameters were derived from a cohort study based on EHEP data (in the case of incidence and prevalence of hypertension), the authors' own assumptions (probability of suffering a stroke), and published research. The authors reported that medium values from the published research were used in order to avoid bias in the evaluation. They did not, however, report any search methods or inclusion criteria. Further, the outcomes post stroke (i.e. QALYs) was derived from a study published in 1977, which may not be applicable today because of improvements in health care and living standards. Since the reporting of the methods was limited, it is not plausible to assess the level of bias present in the estimates.
Validity of estimate of measure of benefit
The estimation of health benefit (active loss of life-days) was derived from a decision tree model, which was appropriate for the study question. The authors did not report the time period during which the outcomes occurred, and it was unclear if discounting was applied or not. The authors only included in their measure of benefit the active loss of life-days due to stroke, but hypertension is a risk factor for other diseases such as coronary heart disease (CHD) that
